Scholar Rock to Announce Q4 Earnings on March 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy SRRK?
Source: seekingalpha
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 49.350
Low
42.00
Averages
50.00
High
60.00
Current: 49.350
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Resubmits Drug Application for Apitegromab, Shares Rise
- Application Resubmission: Scholar Rock announced the resubmission of its U.S. marketing application for apitegromab, aimed at spinal muscular atrophy, resulting in a ~12% premarket share increase, reflecting market optimism regarding potential approval.
- Positive FDA Feedback: Following multiple interactions with the FDA, Scholar Rock confirmed it received guidance on the BLA submission, with no additional corrective actions requested, allowing the company to proceed with the application ahead of Catalent Indiana's reinspection.
- Review Timeline Expectations: The company anticipates that the FDA will accept the BLA within 30 days of resubmission and grant a review period of up to six months, with a potential action date in late September, laying a foundation for future commercialization.
- Ongoing EU Review: The review of Scholar Rock's Marketing Authorization Application for apitegromab in the EU is also underway, with a decision expected in mid-2026, which will further influence the company's international market strategy and development.
See More
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Resubmits Drug Application for Apitegromab, Shares Rise
- Application Resubmission: Scholar Rock announced the resubmission of its U.S. marketing application for apitegromab, aimed at spinal muscular atrophy, resulting in a ~12% premarket share increase, reflecting market optimism regarding potential approval.
- Positive FDA Feedback: Following multiple interactions with the FDA, Scholar Rock confirmed it received guidance on the BLA submission, with no additional corrective actions requested, allowing the company to proceed with the application ahead of Catalent Indiana's reinspection.
- Review Timeline Expectations: The company anticipates that the FDA will accept the BLA within 30 days of resubmission and grant a review period of up to six months, with a potential action date in late September, laying a foundation for future commercialization.
- Ongoing EU Review: The review of Scholar Rock's Marketing Authorization Application for apitegromab in the EU is also underway, with a decision expected in mid-2026, which will further influence the company's international market strategy and development.
See More
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
